Publication: Roles of kisspeptin in IVF/ICSI-treated infertile women and in human granulosa cells
Issued Date
2020-01-01
Resource Type
ISSN
15353699
15353702
15353702
Other identifier(s)
2-s2.0-85097615739
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Biology and Medicine. (2020)
Suggested Citation
Lixian Qin, Chantacha Sitticharoon, Somsin Petyim, Issarawan Keadkraichaiwat, Rungnapa Sririwichitchai, Pailin Maikeaw, Malika Churintaraphan, Chanakarn Sripong Roles of kisspeptin in IVF/ICSI-treated infertile women and in human granulosa cells. Experimental Biology and Medicine. (2020). doi:10.1177/1535370220981006 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60402
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Roles of kisspeptin in IVF/ICSI-treated infertile women and in human granulosa cells
Other Contributor(s)
Abstract
© 2020 by the Society for Experimental Biology and Medicine. Kisspeptin, a crucial central regulator of reproduction, has been used as a trigger in in vitro fertilization (IVF) treatment. This study aimed to investigate the roles of kisspeptin in IVF treatment in infertile females (n = 30); and in steroidogenesis in human granulosa-like tumor cell line (KGN). In the human study, blood was collected at three time points including (1) the beginning of gonadotropin stimulation (Phase I), (2) around eight days after gonadotropin stimulation (Phase II), and (3) on the day of ovum pick-up (Phase III). Follicular fluid (FF) was collected at Phase III. Serum human chorionic gonadotropin (hCG) was measured 15 days after embryo transfer and fetal heart beats were determined around 42 days of menstrual cycle to classify the subjects into successful and unsuccessful groups. FF kisspeptin levels were higher in successful compared with unsuccessful subjects (P < 0.01). Kisspeptin levels were significantly higher in FF than in serum in successful subjects (P < 0.05) but were comparable in unsuccessful subjects. Serum kisspeptin was comparable among three phases in the successful group but its levels in Phase III were significantly lower compared with Phase I in the unsuccessful group (P < 0.01). Serum kisspeptin in Phase II/III had positive correlations with serum E2 in Phases II and III and the outcomes of IVF/intracytoplasmic sperm injection (ICSI) treatment including serum hCG levels. For the cell experiment (n = 3), kisspeptin treatment in the presence of FSH together with IGF-1 enhanced CYP19A1 (aromatase) mRNA expression compared with control. FSH alone increased aromatase concentrations in the supernatant compared with control and kisspeptin at the dose of 10-2 mmol/L with FSH enhanced aromatase concentrations in the supernatant compared with FSH alone (P < 0.001 all). In conclusion, kisspeptin enhanced aromatase expression and secretion and was associated with positive outcomes of IVF/ICSI treatment. Further studies regarding supplementation of kisspeptin could reveal its beneficial effects on IVF/ICSI treatment.